Dasatinib Induces a Response in Malignant Thymoma
Authors:
- 1 December 2006
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (34) , e56-e58
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2006
- Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for SurvivalCancer Research, 2006
- Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse ModelThe American Journal of Pathology, 2006
- Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer CellsCancer Research, 2005
- Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer CellsClinical Cancer Research, 2005
- Protein expression and gene amplification of epidermal growth factor receptor in thymomasCancer, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- c-Src and cooperating partners in human cancerCancer Cell, 2004
- Tyrosine kinase receptor expression in thymomasJournal of Cancer Research and Clinical Oncology, 2004
- KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomasThe Journal of Pathology, 2004